Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Artificial Retina Market

ID: MRFR/MED/2095-CR
208 Pages
Satyendra Maurya, Rahul Gotadki
Last Updated: March 26, 2026

Artificial Retina Implant Market Research Report: Size, Share, Trend Analysis By Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), By Applications (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and By End Users (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World)) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Artificial Retina Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Artificial Retina Market Summary

As per MRFR analysis, the Artificial Retina Market Size was estimated at 2387.09 USD Million in 2024. The Artificial Retina industry is projected to grow from 2614.25 in 2025 to 5803.86 by 2035, exhibiting a compound annual growth rate (CAGR) of 8.37% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Artificial Retina Market is poised for substantial growth driven by technological advancements and increasing prevalence of retinal disorders.

  • North America remains the largest market for artificial retina technologies, reflecting a robust healthcare infrastructure and high patient awareness.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in healthcare and rising incidences of retinal diseases.
  • Diabetic retinopathy represents the largest segment in the artificial retina market, while age-related macular degeneration is the fastest-growing segment due to an aging population.
  • Technological advancements and rising incidence of retinal disorders are key drivers propelling market growth, alongside collaborative research initiatives.

Market Size & Forecast

2024 Market Size 2387.09 (USD Million)
2035 Market Size 5803.86 (USD Million)
CAGR (2025 - 2035) 8.37%

Major Players

Second Sight Medical Products (US), Pixium Vision (FR), Bionic Vision Technologies (AU), Retina Implant AG (DE), Eyenuk (US), Nidek Co., Ltd. (JP), Abbott Laboratories (US), Alcon (CH)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Artificial Retina Market Trends

The Artificial Retina Market is currently experiencing a transformative phase, driven by advancements in technology and increasing prevalence of retinal diseases. The integration of innovative materials and miniaturized devices is enhancing the functionality and effectiveness of artificial retinas. As the global population ages, the demand for solutions addressing vision impairment is likely to rise, prompting further research and development in this field. Additionally, collaborations between academic institutions and industry players appear to be fostering a conducive environment for breakthroughs in artificial vision systems. Moreover, regulatory bodies are becoming more supportive of novel medical devices, which may facilitate faster approvals and market entry for new products. This evolving landscape suggests that the Artificial Retina Market is poised for substantial growth, as stakeholders seek to improve patient outcomes and quality of life. The focus on personalized medicine and tailored solutions could further drive innovation, ensuring that the market remains dynamic and responsive to consumer needs.

Technological Advancements

Recent innovations in materials and device design are enhancing the performance of artificial retinas. These advancements may lead to improved visual acuity and user experience, making devices more appealing to patients.

Rising Incidence of Retinal Disorders

The increasing prevalence of retinal diseases, particularly among the aging population, is driving demand for artificial retina solutions. This trend indicates a growing market opportunity for manufacturers and healthcare providers.

Collaborative Research Initiatives

Partnerships between research institutions and industry leaders are fostering the development of cutting-edge technologies in the artificial retina sector. Such collaborations may accelerate the pace of innovation and product availability.

Artificial Retina Market Drivers

Rising Prevalence of Retinal Disorders

The increasing incidence of retinal disorders globally drives the demand for artificial retina implants. Conditions such as age-related macular degeneration and retinitis pigmentosa are becoming more prevalent, affecting millions. In 2024, the Global Artificial Retina Market Implant Market Industry is valued at 1.24 USD Billion, reflecting the urgent need for innovative solutions. As the population ages, the number of individuals suffering from these conditions is expected to rise, further propelling market growth. The potential for artificial implants to restore vision presents a compelling case for investment in research and development, thereby enhancing the overall market landscape.

Market Segment Insights

By Application: Age-related Macular Degeneration (Largest) vs. Diabetic Retinopathy (Fastest-Growing)

The Artificial Retina Market is significantly influenced by various applications, among which Age-related Macular Degeneration (AMD) holds the largest market share. AMD, which primarily affects the elderly population, accounts for a substantial portion of total cases requiring artificial retinal solutions. In contrast, Diabetic Retinopathy is recognized as the fastest-growing segment due to the increasing prevalence of diabetes globally, prompting demand for effective treatments. Both conditions highlight the pressing need for advanced retinal technologies to enhance patient outcomes. Growth trends in this market segment are primarily driven by rising incidences of retinal diseases and advancements in artificial retina technologies. The aging global population is accelerating the AMD segment, while the increase in diabetes cases is propelling Diabetic Retinopathy's growth. Continuous research and innovations, along with favorable regulatory approvals, are expected to support the expansion of these applications, ultimately leading to improved vision restoration outcomes for patients.

Application: Age-related Macular Degeneration (Dominant) vs. Diabetic Retinopathy (Emerging)

Age-related Macular Degeneration (AMD) is a dominant application within the Artificial Retina Market due to its widespread prevalence and significant impact on vision impairment among the elderly. AMD primarily results in the degeneration of the macula, leading to central vision loss. On the other hand, Diabetic Retinopathy is emerging rapidly as a crucial application owing to the rising global diabetes epidemic. This condition causes damage to the retinal blood vessels, culminating in vision complications. Both segments exhibit distinct characteristics—while AMD caters predominantly to an older demographic requiring solutions for age-related vision loss, Diabetic Retinopathy demands innovative therapeutic approaches targeted at younger, diabetic populations. The competitive landscape for these applications is evolving as more players invest in tailored artificial retina technologies.

By Technology: Electronic Retinal Implants (Largest) vs. Subretinal Implants (Fastest-Growing)

The technology segment of the Artificial Retina Market showcases a diverse landscape with varying shares among its key components. Electronic retinal implants hold the largest portion of the market due to their established clinical applications and recent advancements enhancing their efficacy. Meanwhile, subretinal implants have gained momentum, attracting attention from healthcare professionals and researchers alike for their potential to restore vision. These implants are complemented by other technologies like photovoltaic retinal implants and optogenetic therapy, which, while smaller in market share, contribute significantly to the innovation landscape.

Technology: Electronic Retinal Implants (Dominant) vs. Subretinal Implants (Emerging)

Electronic retinal implants are well-recognized for their effectiveness in managing retinal degenerative conditions, making them a dominant force in the market. Their design focuses on direct interaction with retinal cells to improve vision through electrical stimulation. Conversely, subretinal implants are emerging as promising alternatives due to advancements in biocompatible materials and wireless technology. These emerging implants aim to convert light into usable electrical signals for retinal repair, indicating a shift in approaches towards vision restoration. Together, these technologies illustrate a burgeoning area of growth fueled by advancements in biomedical engineering and a rising demand for innovative treatments.

By End User: Hospitals (Largest) vs. Ophthalmology Clinics (Fastest-Growing)

The Artificial Retina Market exhibits a diverse range of end users, with hospitals commanding the largest share due to their comprehensive capabilities and infrastructure that support advanced surgical procedures. They serve as primary institutions for the implementation of artificial retina technologies, providing specialized care to patients with retinal degenerative conditions. In contrast, ophthalmology clinics are emerging as the fastest-growing segment, leveraging their focused services and specialized expertise to cater to an increasing number of patients seeking innovative vision restoration solutions.

Hospitals (Dominant) vs. Ophthalmology Clinics (Emerging)

Hospitals play a dominant role in the Artificial Retina Market, as they possess the essential resources and advanced technology to perform intricate surgical procedures required for artificial retina implantation. Their extensive networks and multidisciplinary teams ensure comprehensive patient care, enhancing the adoption of artificial retina solutions. On the other hand, ophthalmology clinics are rapidly emerging due to their specialized focus on eye care, which allows for tailored treatment options and personalized care. This segment's growth is driven by an increasing patient population seeking outpatient services and specialized treatments, positioning these clinics as critical players in the overall market.

By Distribution Channel: Direct Sales (Largest) vs. Online Sales (Fastest-Growing)

In the Artificial Retina Market, the distribution channels play a crucial role in shaping the industry's landscape. Direct Sales hold the largest market share as healthcare providers and manufacturers favor personal interactions and direct relationships with clinics. Meanwhile, Online Sales have emerged as a significant channel, as the trend towards digitalization drives more customers to purchase devices online. The convenience, enhanced accessibility, and ongoing advancements in e-commerce platforms have bolstered this segment's prevalence among newer demographics, allowing it to rapidly gain traction in recent years.

Direct Sales (Dominant) vs. Online Sales (Emerging)

Direct Sales in the Artificial Retina Market have established themselves as a dominant force, primarily catering to specialized healthcare providers who prioritize installation support and personalized service when integrating artificial retina systems into their practices. This approach allows for a tailored customer experience and strong relationship building. On the other hand, Online Sales are viewed as an emerging segment, largely appealing to tech-savvy patients and providers seeking convenience. This channel benefits from growing trust in online purchasing, providing an avenue for companies to reach broader audiences while adapting quickly to the needs of a digital consumer environment, hence asserting its position as a fast-growing preference.

By Product Type: Implantable Devices (Largest) vs. Wearable Devices (Fastest-Growing)

In the Artificial Retina Market, the segment distribution reveals that Implantable Devices hold the largest market share, reflecting their established presence and reliability in treating various types of vision impairments. These devices have been crucial in advancing treatment options, providing patients with improved visual capabilities. On the other hand, Wearable Devices are emerging as significant contenders, steadily increasing their market share as they incorporate advanced technology and user-centric designs aimed at enhancing user experience. The growth trends within the Artificial Retina Market indicate a robust demand for innovation and accessibility. Wearable Devices are anticipated to experience the fastest growth due to their convenience and the rising interest in personalized healthcare solutions. Factors driving this growth include technological advancements, increased funding for research and development, and an expanding awareness of vision health. Additionally, the integration of smart technologies into these devices enhances their appeal to consumers seeking modern solutions for vision restoration.

Implantable Devices (Dominant) vs. Wearable Devices (Emerging)

Implantable Devices in the Artificial Retina Market are primarily designed for surgical implantation and offer a permanent solution for vision restoration. Their characteristics include a proven efficacy profile and the ability to integrate with the human body, ensuring long-term support for patients with significant vision loss. As advancements continue in miniaturization and biocompatibility, these devices are expected to maintain dominance due to their clinical reliability and strong track record. Conversely, Wearable Devices represent an emerging trend, designed to be user-friendly and less invasive, catering specifically to consumers seeking immediate and flexible solutions for visual assistance. These devices harness cutting-edge technologies such as augmented reality and connectivity features, fostering user engagement and satisfaction. Their adaptability to different lifestyles and quick integration into daily routines position them as a complementary alternative to traditional implantable devices, appealing particularly to younger demographics and tech-savvy individuals.

Get more detailed insights about Artificial Retina Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is poised to maintain its leadership in the artificial retina market, holding a significant share of 1192.25 million in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of retinal diseases, and substantial investments in R&D. Regulatory support from agencies like the FDA further catalyzes innovation, ensuring rapid market entry for new technologies. The competitive landscape is robust, featuring key players such as Second Sight Medical Products and Abbott Laboratories. The U.S. leads the market, supported by a strong focus on technological advancements and patient-centric solutions. Canada and Mexico are also emerging as important markets, contributing to the overall growth through collaborations and partnerships in the healthcare sector.

Europe : Emerging Market with Potential

Europe's artificial retina market is valued at 715.0 million, reflecting a growing demand for innovative solutions in vision restoration. The region benefits from a strong regulatory framework, with the European Medicines Agency (EMA) actively promoting advancements in medical devices. Increasing awareness of retinal disorders and supportive healthcare policies are key drivers of market growth. Leading countries include Germany, France, and the UK, where significant investments in healthcare technology are evident. Companies like Pixium Vision and Retina Implant AG are at the forefront, driving innovation and expanding their market presence. The competitive landscape is characterized by collaborations between tech firms and healthcare providers, enhancing the development of artificial retina solutions.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region, with a market size of 380.0 million, is rapidly emerging in the artificial retina sector. Factors such as increasing healthcare expenditure, rising awareness of retinal diseases, and government initiatives to improve healthcare access are propelling market growth. The region is witnessing a shift towards advanced medical technologies, supported by favorable regulatory environments. Countries like Japan, Australia, and China are leading the charge, with significant contributions from local companies like Bionic Vision Technologies and Nidek Co., Ltd. The competitive landscape is evolving, with a focus on partnerships and collaborations to enhance product offerings and market reach. The growing demand for innovative solutions is expected to drive further advancements in the sector.

Middle East and Africa : Emerging Market Opportunities

The Middle East and Africa (MEA) region, with a market size of 99.84 million, presents emerging opportunities in the artificial retina market. Factors such as increasing healthcare investments, rising prevalence of eye disorders, and a growing focus on advanced medical technologies are driving market growth. Regulatory bodies are beginning to establish frameworks to support the introduction of innovative medical devices, enhancing market potential. Countries like South Africa and the UAE are at the forefront, with increasing collaborations between local and international firms. The presence of key players such as Eyenuk and Alcon is fostering competition and innovation. As healthcare infrastructure improves, the region is expected to see significant advancements in artificial retina technologies, catering to the growing demand for vision restoration solutions.

Artificial Retina Market Regional Image

Key Players and Competitive Insights

The Artificial Retina Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and increasing investments in research and development. Key players are focusing on innovation and strategic partnerships to enhance their product offerings and market reach. For instance, Second Sight Medical Products (US) has been at the forefront of developing advanced retinal prosthetics, emphasizing the integration of digital technologies to improve patient outcomes. Similarly, Pixium Vision (FR) is leveraging its expertise in bioelectronics to create innovative solutions that address the needs of patients with retinal diseases, thereby positioning itself as a leader in the market.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing their supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Bionic Vision Technologies (AU) and Retina Implant AG (DE) is shaping the competitive structure, as they engage in strategic collaborations and mergers to strengthen their market positions.

In November Second Sight Medical Products (US) announced a partnership with a leading technology firm to develop a next-generation artificial retina system that incorporates AI-driven features. This strategic move is likely to enhance the functionality of their products, potentially leading to improved visual outcomes for patients. The collaboration underscores the importance of integrating cutting-edge technology into medical devices, which may set a new standard in the industry.

In October Pixium Vision (FR) launched a clinical trial for its latest retinal implant, which aims to restore vision in patients with severe retinal degeneration. This initiative not only demonstrates the company's commitment to innovation but also highlights its proactive approach to addressing unmet medical needs. The successful outcome of this trial could significantly bolster Pixium's market presence and credibility.

In September Bionic Vision Technologies (AU) secured a substantial investment to expand its research capabilities and accelerate the development of its retinal prosthesis. This funding is expected to enhance the company's R&D efforts, allowing for the exploration of new technologies that could revolutionize the treatment of vision loss. Such financial backing is crucial for sustaining innovation in a competitive market.

As of December the Artificial Retina Market is witnessing trends such as digitalization and AI integration, which are redefining competitive dynamics. Strategic alliances are becoming increasingly vital, as companies recognize the need to collaborate to leverage complementary strengths. The focus appears to be shifting from price-based competition to differentiation through innovation and technology. This evolution suggests that companies that prioritize R&D and supply chain reliability will likely emerge as leaders in the market.

Key Companies in the Artificial Retina Market include

Industry Developments

  • Q3 2024: Pixium Vision secures €15 million funding to advance Prima System artificial retina Pixium Vision announced a €15 million funding round to accelerate the clinical development and commercialization of its Prima System, an artificial retina implant designed to restore vision in patients with advanced retinal diseases.
  • Q2 2024: Nano Retina receives CE Mark approval for NR600 artificial retina implant Nano Retina announced it has received CE Mark approval for its NR600 artificial retina implant, allowing the device to be marketed and sold in the European Union for patients with severe vision loss due to retinal degenerative diseases.
  • Q2 2024: Pixium Vision announces partnership with Stanford University to advance artificial retina research Pixium Vision entered into a research partnership with Stanford University to collaborate on next-generation artificial retina technologies, focusing on improving implant performance and patient outcomes.
  • Q1 2024: Second Sight Medical Products appoints new CEO to lead artificial retina business Second Sight Medical Products announced the appointment of a new Chief Executive Officer to drive the company’s strategy and growth in the artificial retina sector.
  • Q2 2024: Nano Retina and Bionic Vision Technologies announce strategic partnership for global distribution Nano Retina and Bionic Vision Technologies formed a strategic partnership to jointly distribute and commercialize their artificial retina implants in key international markets.
  • Q2 2024: Pixium Vision receives FDA Breakthrough Device Designation for Prima System Pixium Vision announced that its Prima System artificial retina implant has received Breakthrough Device Designation from the U.S. FDA, expediting its regulatory review process for patients with advanced dry age-related macular degeneration.
  • Q1 2024: Bionic Vision Technologies raises $20 million to expand artificial retina trials Bionic Vision Technologies completed a $20 million funding round to support expanded clinical trials of its artificial retina device for patients with inherited retinal diseases.
  • Q2 2024: Second Sight Medical Products announces new manufacturing facility for artificial retina devices Second Sight Medical Products opened a new manufacturing facility dedicated to the production of its artificial retina implants, aiming to scale up supply for global markets.
  • Q3 2024: Retina Implant AG secures regulatory approval for Alpha AMS in Japan Retina Implant AG received regulatory approval in Japan for its Alpha AMS subretinal implant, enabling the company to market its artificial retina device to Japanese patients with retinitis pigmentosa.
  • Q2 2024: Pixium Vision and Nano Retina sign co-development agreement for next-gen artificial retina Pixium Vision and Nano Retina entered a co-development agreement to jointly research and develop next-generation artificial retina technologies, combining their expertise in microelectronics and neurostimulation.
  • Q1 2024: Second Sight Medical Products wins contract with U.S. Department of Veterans Affairs for artificial retina devices Second Sight Medical Products secured a contract with the U.S. Department of Veterans Affairs to supply artificial retina implants to eligible veterans with vision loss due to retinal degenerative diseases.
  • Q2 2024: Retina Implant AG announces partnership with Johns Hopkins University for clinical research Retina Implant AG partnered with Johns Hopkins University to conduct clinical research on the long-term efficacy and safety of its Alpha AMS artificial retina implant.

Future Outlook

Artificial Retina Market Future Outlook

The Artificial Retina Market is projected to grow at an 8.37% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of retinal diseases, and rising healthcare investments.

New opportunities lie in:

  • Development of personalized artificial retina solutions for diverse patient needs.
  • Expansion of telemedicine platforms for remote patient monitoring and support.
  • Strategic partnerships with healthcare providers for integrated treatment pathways.

By 2035, the Artificial Retina Market is expected to achieve substantial growth, reflecting advancements and increased accessibility.

Market Segmentation

Artificial Retina Market End User Outlook

  • Hospitals
  • Ophthalmology Clinics
  • Research Institutions
  • Home Care Settings

Artificial Retina Market Material Outlook

  • Silicone
  • Polymer
  • Biocompatible Materials
  • Metals

Artificial Retina Market Technology Outlook

  • Subretinal Implant
  • Epiretinal Implant
  • Suprachoroidal Implant
  • Optogenetics

Artificial Retina Market Application Outlook

  • Retinal Degeneration
  • Retinal Detachment
  • Diabetic Retinopathy
  • Age-related Macular Degeneration

Artificial Retina Market Product Type Outlook

  • Implantable Devices
  • Wearable Devices
  • Diagnostic Devices

Report Scope

MARKET SIZE 2024 2387.09(USD Million)
MARKET SIZE 2025 2614.25(USD Million)
MARKET SIZE 2035 5803.86(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 8.37% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Second Sight Medical Products (US), Pixium Vision (FR), Bionic Vision Technologies (AU), Retina Implant AG (DE), Eyenuk (US), Nidek Co., Ltd. (JP), Abbott Laboratories (US), Alcon (CH)
Segments Covered Application, Technology, End User, Product Type, Material
Key Market Opportunities Advancements in neuroprosthetics enhance vision restoration options in the Artificial Retina Market.
Key Market Dynamics Technological advancements and regulatory support drive innovation and competition in the Artificial Retina Market.
Countries Covered North America, Europe, APAC, South America, MEA

Market Highlights

FAQs

What is the projected market valuation of the Artificial Retina Market by 2035?

The projected market valuation of the Artificial Retina Market is expected to reach 5803.86 USD Million by 2035.

What was the market valuation of the Artificial Retina Market in 2024?

The overall market valuation of the Artificial Retina Market was 2387.09 USD Million in 2024.

What is the expected CAGR for the Artificial Retina Market during the forecast period 2025 - 2035?

The expected CAGR for the Artificial Retina Market during the forecast period 2025 - 2035 is 8.37%.

Which companies are considered key players in the Artificial Retina Market?

Key players in the Artificial Retina Market include Second Sight Medical Products, Pixium Vision, Bionic Vision Technologies, and others.

What are the main applications driving the Artificial Retina Market?

The main applications driving the Artificial Retina Market include Retinal Degeneration, Retinal Detachment, Diabetic Retinopathy, and Age-related Macular Degeneration.

What is the market size for Retinal Degeneration applications in the Artificial Retina Market?

The market size for Retinal Degeneration applications was 800.0 USD Million in 2024 and is projected to reach 2000.0 USD Million by 2035.

How does the market for Electronic Retinal Implants compare to other technologies?

The market for Electronic Retinal Implants was valued at 800.0 USD Million in 2024 and is expected to grow to 2000.0 USD Million by 2035.

What distribution channels are utilized in the Artificial Retina Market?

Distribution channels in the Artificial Retina Market include Direct Sales, Online Sales, Distributors, and Healthcare Providers.

What is the projected market size for Healthcare Providers in the Artificial Retina Market?

The projected market size for Healthcare Providers is expected to grow from 987.09 USD Million in 2024 to 2303.86 USD Million by 2035.

What types of products are included in the Artificial Retina Market?

The Artificial Retina Market includes product types such as Implantable Devices, Wearable Devices, Surgical Instruments, and Diagnostic Equipment.
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed ophthalmology journals, clinical trial registries, and authoritative vision health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), European Medicines Agency (EMA) Medical Device Coordination Group (MDCG), Pharmaceuticals and Medical Devices Agency (PMDA) Japan, National Medical Products Administration (NMPA) China, Health Canada, and Therapeutic Goods Administration (TGA) Australia. Clinical and epidemiological data were sourced from the National Eye Institute (NEI) National Eye Health Education Program, World Health Organization (WHO) Global Health Observatory Vision Impairment Database, Centers for Disease Control and Prevention (CDC) Vision Health Initiative, and the International Agency for the Prevention of Blindness (IAPB) Vision Atlas. Professional societies including the American Academy of Ophthalmology (AAO), European Society of Retina Specialists (EURETINA), American Society of Retina Specialists (ASRS), and Association for Research in Vision and Ophthalmology (ARVO) provided procedural guidelines and prevalence data. Academic databases included PubMed/MEDLINE, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP), and the Cochrane Database of Systematic Reviews for meta-analyses on retinal prosthesis efficacy. Disease-specific registries such as the My Retina Tracker Registry (Foundation Fighting Blindness), IRD (Inherited Retinal Disease) registries from the EU-Eye project, and national blindness registries from Germany (Retina Implant Registry) and France (FERDI) were consulted for epidemiological statistics on retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy prevalence. Patent databases (USPTO, EPO, WIPO) were analyzed for neuroprosthetic and optogenetic technology trends. These sources were used to collect implant procedure statistics, regulatory approval pathways (PMA, CE Mark, Shonin), clinical safety and efficacy studies, patient demographic trends, and competitive landscape analysis for epiretinal implants (Argus II), subretinal implants (Alpha AMS, PRIMA), suprachoroidal devices (Bionic Eye), and emerging optogenetic therapies.

Primary Research

In the primary research process, stakeholders from both the supply and demand sides were interviewed to acquire qualitative and quantitative insights that were specific to neuroprosthetic vision restoration technologies. Supply-side sources encompassed Chief Executive Officers, VPs of R&D and Clinical Affairs, regulatory affairs directors, and commercial leads from artificial retina device manufacturers, microelectrode suppliers, and neurostimulation technology developers. Demand-side sources included reimbursement specialists from academic medical centers and specialized ophthalmology clinics, hospital procurement officers from tertiary eye care centers, ophthalmology department chiefs, and vitreoretinal surgeons. Primary research has confirmed clinical trial timelines for next-generation optogenetic devices, validated market segmentation between implantable and wearable technologies, and collected insights on surgical adoption patterns, pricing strategies for high-cost implantable devices (USD 100,000-150,000 per procedure), and reimbursement dynamics for humanitarian device exemptions (HDE) and DRG codes for retinal prosthesis implantation.

Primary Respondent Breakdown:

By Designation: C-level Executives (28%), Director Level (33%), Department Heads/Managers (24%), Clinical Researchers/Others (15%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

By Stakeholder Type: Device Manufacturers (45%), Healthcare Providers/Clinicians (30%), Research Institutions (15%), Payers/Regulatory Consultants (10%)

Market Size Estimation

Global market valuation was derived through revenue mapping and implant procedure volume analysis specific to retinal prosthetics and vision restoration devices. The methodology included:

Identification of 25+ key manufacturers across North America, Europe, Asia-Pacific, and Israel, including pure-play artificial retina developers and diversified ophthalmic device companies

Product mapping across epiretinal implants (Argus II/Orion), subretinal implants (Alpha AMS, PRIMA System), suprachoroidal implants (Bionic Eye), and emerging optogenetic wearable devices (goggles plus gene therapy combinations)

Analysis of reported and modeled annual revenues specific to artificial retina portfolios, including direct device sales, surgical accessories, and maintenance/service contracts

Coverage of manufacturers representing 75-80% of global market share in 2024, with specific focus on FDA HDE-approved and CE Mark-certified devices

Extrapolation using bottom-up (eligible patient population × diagnosis rate × implant adoption rate × ASP by country/region) and top-down (manufacturer revenue validation and neurostimulation market allocation) approaches to derive segment-specific valuations for AMD, retinitis pigmentosa, and diabetic retinopathy indications

Procedure volume triangulation through national health insurance claims data (US Medicare DRG 927, German OPS 5-924, Japanese NHI retina procedure codes) and hospital discharge databases

Pricing analysis across tender-based procurement in EU member states, reference pricing in Japan, and bundled payment models in US academic medical centers

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓